ABBV
AbbVie · Health Care
3.0%
typical move (median |reaction| of last 8)
2026-10-30 pre · likely
next expected · estimated from pattern
24
scored events
Last eight reactions
2025-10-31 → 2026-10-05
| date | session | reaction | |move| | excess 5s | excess 20s |
|---|---|---|---|---|---|
| 2026-10-05 | post | +0.4% | 0.4% | +2.9% | n/a |
| 2026-07-31 | pre | -2.6% | 2.6% | -5.5% | -1.1% |
| 2026-07-06 | post | -0.1% | 0.1% | -4.4% | -6.7% |
| 2026-04-29 | pre | +3.4% | 3.4% | -2.8% | +1.0% |
| 2026-04-06 | pre | -1.0% | 1.0% | -4.2% | -7.4% |
| 2026-02-04 | pre | -3.9% | 3.9% | +0.9% | +7.7% |
| 2026-01-07 | post | -4.0% | 4.0% | -3.8% | +0.3% |
| 2025-10-31 | pre | -4.5% | 4.5% | +2.1% | +3.4% |
Source filings
2026-10-05 · 8-K press release
AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended September 30, 2026 Full-Year Ended December 31, 2026 A
2026-07-31 · 8-K press release
AbbVie Reports Second-Quarter 2026 Financial Results • Reports Second-Quarter Diluted EPS of $2.03 on a GAAP Basis, an Increase of 290.4 Percent; Adjusted Diluted EPS of $3.65, an Increase of 22.9 Per
2026-07-06 · 8-K press release
AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended June 30, 2026 Full-Year Ended December 31, 2026 Acquir
2026-04-29 · 8-K press release
AbbVie Reports First-Quarter 2026 Financial Results • Reports First-Quarter Diluted EPS of $0.39 on a GAAP Basis, a Decrease of 45.8 Percent; Adjusted Diluted EPS of $2.65, an Increase of 7.7 Percent;
2026-04-06 · 8-K press release
AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended March 31, 2026 Full-Year Ended December 31, 2026 Acqui
2026-02-04 · 8-K press release
AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results • Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.
2026-01-07 · 8-K press release
AbbVie Inc. Guidance Including the Impact of Acquired IPR&D and Milestones Expense (Unaudited) (in millions, except per share data) Quarter Ended December 31, 2025 Full-Year Ended December 31, 2025 Ac
2025-10-31 · 8-K press release
AbbVie Reports Third-Quarter 2025 Financial Results • Reports Third-Quarter Diluted EPS of $0.10 on a GAAP Basis, a Decrease of 88.6 Percent; Adjusted Diluted EPS of $1.86, a Decrease of 38.0 Percent;